Sebivo (Tyzeka) was approved in South Korea a few days ago. This is the first approval in East Asia, where HBV is endemic. (Source: today’s NVS webcast)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”